Scribe Therapeutics Raises $100M Series B Financing to Further Develop 'CRISPR by Design' Platform and Pipeline of Breakthrough Genetic Medicines
|
March 31, 2021
X min read
Scribe’s fully integrated evergreen platform accelerates the development of best-in-class in vivo therapies that treat the underlying cause of disease
|
March 31, 2021
Share on Social
More like this
News
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
January 13, 2025
Read Now
Press
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
January 13, 2025
Read Now
News
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
Read Now
Press
Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
Read Now
News
From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need
December 6, 2024
Forbes Healthcare Summit
Read Now
Press
From The Lab To The Clinic: Developing And Delivering The Next Generation Of Therapies To Patients In Need
December 6, 2024
Forbes Healthcare Summit
Read Now
